ClinicalTrials.gg
Drug

Latanoprost clinical trials

Also written Xalatan, T2345 and PhXA41.

studies test it
99
open now
5
in phase 3
20
first study started
1992

How each study uses Latanoprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Latanoprost studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
5 Jun 1996 · XALATAN · NDA 020597 (FDA, Drugs@FDA)
European Union
7 Jan 2021 · Roclanda · EMEA/H/C/005107 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Latanoprost
32
Latanoprost 0.005%
7
Latanoprost-PPDS
6
Latanoprost 0.005% Ophthalmic Solution
5
Latanoprost (0.005%)
4

Brand

Xalatan
28

Development codes

T2345
3
PhXA41
3

In one entry with another drug

Given together, or one or the other

Latanoprost/Timolol
3

Studies by the year they started

96 studies that test it; most in 2009 (10)

Studies that test Latanoprost, by start year
YearStudies
19922
19931
20001
20011
20023
20034
20057
20067
20076
20089
200910
20107
20116
20122
20133
20145
20152
20162
20183
20191
20202
20212
20223
20231
20243
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
3
Phase 2
25
Phase 3
20
Phase 4
36
No phase
14

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 52 · Other 47

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Mati Therapeutics Inc. (8) · Allergan (6) · Alcon Research (4) · Laboratoires Thea (3) · Pfizer (3) · Zagazig University (2) · University of Nebraska (2)

Often tested with

Tested in the same studies.

Timolol (14) · Travoprost (14) · Bimatoprost (11) · Dorzolamide (7) · Brimonidine (5) · Xalacom (3) · Tafluprost (2) · Brinzolamide (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test Latanoprost.

Studies

Open first, then newest update. How each study uses Latanoprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 99

See all 99 studies that test Latanoprost →

Given beside what is tested · 14 — Latanoprost is usual care or a partner of the new treatment
As the comparator · 63 — what is tested is compared with Latanoprost

Showing 20 of 63.

Codes

What other systems call Latanoprost · ClinicalTrials.gg INT006705

  • MeSH (NLM) D000077338LatanoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 6Z5B6HVF6OLATANOPROSTConfirmed FDA, NLM, Wikidata
  • RxNorm 43611Confirmed FDA, Wikidata
  • Wikidata Q634959latanoprostConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C29151LatanoprostOne source FDA
  • DrugBank DB00654One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.